Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Inclusion Criteria: * Patients with histologically documented metastatic, recurrent, or locally unresectable solid tumors which have progressed after one line of therapy, or for which no curative therapy is available. Patients with lymphoma who have received adequate exposure to standard of care therapy and for whom no curative therapy is available are also eligible (this trial will enroll a minimum of 5 lymphoma patients) * Patients must have measurable or evaluable disease * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * Leukocytes \>= 2,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL (solid tumor patients) \>= 75,000/mcL (lymphoma patients) * Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) /alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 2.5 x institutional ULN * Serum creatinine =\< 1.5 x institutional ULN OR creatinine clearance \>= 50 mL/min/1.73 m\^2 by Cockcroft-Gault * Any prior therapy must have been completed \>= 4 weeks (6 weeks for nitrosoureas and mitomycin C) or, if known, \>= 5 half-lives of the prior agent (whichever is shorter) prior to enrollment on protocol (minimum of 1 week between prior therapy and study enrollment), and the participant must have recovered to eligibility levels from prior toxicity; prior definitive radiation should have been com…